CT Imaging for Guiding PA-TACE for HCC

Carcinoma, Hepatocellular Clinical Trial

Official title:

CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06156748
• Other study ID #: 2019-KY-021-01
• Status: Recruiting
• Start date: October 1, 2019
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: Zhujiang Hospital
• Contact: Li, MD
• Phone: 86-020-62783269
• Email: lixinmingsmu[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1488
• Est. completion date: December 31, 2025
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• CT scans acquired no more than one month before surgery

• Confirmation of HCC diagnosis by pathological examination

• Curative surgical resection

Exclusion Criteria:

• Prior antitumor treatment

• Macrovascular thrombosis or metastasis

• Perioperative mortality

• Unqualified image artifacts

• Tumor rupture

• MVI status not reported

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Procedure:
• postoperative adjuvant transarterial chemoembolization
HCC patients received hepatectomy and PA-TACE.

Locations

Country	Name	City	State
China	ZhuJiang Hospital of Southern Medical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.	the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.